FDA considers new dose for Esai’s Dacogen

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 8
Volume 18
Issue 8

The FDA is reviewing Eisai Corporation of North America’s supplemental new drug application for Dacogen (decitabine for injection). The review is for an alternative five-day dosing regimen to treat patients with myelodysplastic syndromes.

The FDA is reviewing Eisai Corporation of North America's supplemental new drug application for Dacogen (decitabine for injection). The review is for an alternative five-day dosing regimen to treat patients with myelodysplastic syndromes.

Currently, Dacogen is approved for use as a three-day regimen for the bone marrow disease at a dose of 15 mg/m2. The regimen involves continuous IV infusion over three hours repeated every eight hours for three consecutive days, which is then repeated every six weeks. The alternative dose Eisai submitted to FDA is a single daily dose with a reduced administration time.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Related Content